SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern
Open accessThe DOI matches its Crossref record; 100 of the 100 references it cites were found in a registry or an index.
Abstract
SARS-CoV-2 from alpha to epsilon: As battles to contain the COVID-19 pandemic continue, attention is focused on emerging variants of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus that have been deemed variants of concern because they are resistant to antibodies elicited by infection or vaccination or they increase transmissibility or disease severity. Three papers used functional and structural studies to explore how mutations in the viral spike protein affect its ability to infect host cells and to evade host immunity. Gobeil et al . looked at a variant spike protein involved in transmission between minks and humans, as well as the B1.1.7 (alpha), B.1.351 (beta), and P1 (gamma) spike variants; Cai et al . focused on the alpha and beta variants; and McCallum et al . discuss the properties of the spike protein from the B1.1.427/B.1.429 (epsilon) variant. Together, these papers show a balance among mutations that enhance stability, those that increase binding to the human receptor ACE2, and those that confer resistance to neutralizing antibodies. —VV
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Fig. 2. B.1.427/B.1.429 S pseudotyped virus neutralization by vaccine-elicited and COVID-19 convalescent plasma. (A, B, E, and F) Neutralizing Ab titers [mean inhibition dilution (ID50)] shown as pairwise connected [(A) and (E)] or GMT [(B) and (F)] against MLV [(A) and (B)] or VSV [(E) and (F)] pseudotyped viruses harboring G614 SARS-CoV-2 S or B.1.427/B.1.429 (B.1.429) S determined using plasma from individuals who received two doses of the Moderna mRNA-1273 vaccine (blue). (C, D, G, and H) Neutralizing Ab titers (ID50) shown as pairwise connected [(C) and (G)] or GMT [(D) and (H)] against MLV [(C) and (D)] or VSV [(G) and (H)] pseudotyped viruses harboring G614 SARS-CoV-2 S or B.1.427/B.1.429 (B.1.429) S determined using plasma from individuals who received two doses of the Pfizer/BioNtech BNT162b2 mRNA vaccine (red). (I and J) Neutralizing Ab ID50 (I) and GMT (J) titers against VSV pseudotyped viruses harboring D614 SARS-CoV-2 S, B.1.427/B.1.429 S, B.1.1.7 S, B.1.351 S, or P.1 S determined using plasma from naïve (blue) and previously infected (red) individuals who received two doses of the Pfizer/BioNtech BNT162b2 mRNA vaccine. “Naïve” indicates vaccinated individuals who had not been previously infected with SARS-CoV-2; “immune” refers to vaccinated individuals who had been previously infected with SARS-CoV-2. (K and L) Neutralizing Ab ID50 (K) and GMT (L) titers against VSV pseudotyped viruses harboring D614 SARS-CoV-2 S, B.1.427/B.1.429 S, B.1.1.7 S, B.1.351 S, or P.1 S determined using plasma from convalescent individuals who were infected with WT SARS-CoV-2. Neutralization data shown in (A) to (H) and (I) to (L) were performed using 293T-ACE2 and VeroE6-TMPRSS2, respectively. Data are average of n = 2 replicates.](https://figures.cochat.ai/paper-figures/e2b6f8f874fc4753bb3a1e70b39ac8ee/sars-cov-2-immune-evasion-by-the-b-1-427-b-1-429-variant-of-concern-figure-2.jpg)



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This signal peptide modification resulted in a total loss of neutralization by ten NTD-specific antibodies [40].”
From Waves and variants of SARS-CoV-2: understanding the causes and effect of the COVID-19 catastrophe (2022) · cites this paper as [40]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Of 34 convalescent plasma samples from persons infected with the Alpha variant, 59% had 3-fold to 10-fold reduced neutralizing activity and 18% had >10-fold reduced neutralizing activity to the Beta variant 99,104,221 .”
From The biological and clinical significance of emerging SARS-CoV-2 variants (2021) · cites this paper as [221]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“A novel mechanism of immune evasion was studied in the Epsilon variant, where the other two mutations remodeled NTD by shifting the signal peptide cleavage site in the NTD antigenic supersite and forming a new disulfide bond.”
From Waves and variants of SARS-CoV-2: understanding the causes and effect of the COVID-19 catastrophe (2022) · cites this paper as [40]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MAFFT Multiple Sequence Alignment Software Version 7: Improvements in Performance and Usability
Katoh, K., & Standley, D. M. (2013) · Molecular Biology and Evolution · doi:10.1093/molbev/mst010 · Cited by 46,209
UCSF Chimera—A visualization system for exploratory research and analysis
Pettersen, E. F., Goddard, T. D., Huang, C. C., Couch, G. S., Greenblatt, D. M., Meng, E. C., & Ferrin, T. E. (2004) · Journal of Computational Chemistry · doi:10.1002/jcc.20084 · Cited by 45,828
Features and development of Coot
Emsley, P., Lohkamp, B., Scott, W. G., & Cowtan, K. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444910007493 · Cited by 29,915
Hoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler, T., Erichsen, S., Schiergens, T. S., Herrler, G., Wu, N.-H., Nitsche, A., et al. (2020) · Cell · doi:10.1016/j.cell.2020.02.052 · Cited by 20,286
MolProbity : all-atom structure validation for macromolecular crystallography
Chen, V. B., Arendall, W. B., Headd, J. J., Keedy, D. A., Immormino, R. M., Kapral, G. J., Murray, L. W., Richardson, J. S., & Richardson, D. C. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909042073 · Cited by 14,115
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Structure, function and antigenicity of the SARS-CoV-2 spike glycoprotein
Walls, A. C., Park, Y.-J., Tortorici, M. A., Wall, A., McGuire, A. T., & Veesler, D. (2020) · doi:10.1101/2020.02.19.956581 · Cited by 8,586
Self-citationLiebschner, D., Afonine, P. V., Baker, M. L., Bunkóczi, G., Chen, V. B., Croll, T. I., Hintze, B., Hung, L.-W., Jain, S., McCoy, A. J., et al. (2019) · Acta Crystallographica Section D Structural Biology · doi:10.1107/s2059798319011471 · Cited by 7,953
UCSF ChimeraX: Meeting modern challenges in visualization and analysis
Goddard, T. D., Huang, C. C., Meng, E. C., Pettersen, E. F., Couch, G. S., Morris, J. H., & Ferrin, T. E. (2018) · Protein Science · doi:10.1002/pro.3235 · Cited by 5,267
New tools for automated high-resolution cryo-EM structure determination in RELION-3
Zivanov, J., Nakane, T., Forsberg, B. O., Kimanius, D., Hagen, W. J., Lindahl, E., & Scheres, S. H. (2018) · eLife · doi:10.7554/elife.42166 · Cited by 4,621
Cited by
Items 201–300 of 426
Rashid, F., Suleman, M., Shah, A., Dzakah, E. E., Chen, S., Wang, H., & Tang, S. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.789062 · Cited by 18
Severe Acute Respiratory Syndrome Type 2‐Causing Coronavirus: Variants and Preventive Strategies
Aydoğdu, M. O., Rohn, J. L., Jafari, N. V., Brako, F., Homer‐Vanniasinkam, S., & Edirisinghe, M. J. (2022) · Advanced Science · doi:10.1002/advs.202104495 · Cited by 20
Potent antibody immunity to SARS‐CoV‐2 variants elicited by a third dose of inactivated vaccine
Ju, B., Zhou, B., Song, S., Fan, Q., Ge, X., Wang, H., Cheng, L., Guo, H., Shu, D., Liu, L., et al. (2022) · Clinical and Translational Medicine · doi:10.1002/ctm2.732 · Cited by 18
Virion morphology and on-virus spike protein structures of diverse SARS-CoV-2 variants
Ke, Z., Peacock, T. P., Brown, J. C., Sheppard, C., Croll, T. I., Kotecha, A., Goldhill, D. H., Barclay, W., & Briggs, J. A. G. (2024) · The EMBO Journal · doi:10.1038/s44318-024-00303-1 · Cited by 16
“Taking advantage of this established method, cryo-EM has been used to determine structures of recombinant, purified S trimers from emerging variants including Alpha, Beta, and Gamma 29–32 , as well as Delta, Kappa, and Epsilon 26,33–35 and, more recently, Omicron 36,37 .”
Sensitivity theorems of a model of multiple imperfect vaccines for COVID-19
Aguilar-Canto, F. J., de León, U. A.-P., & Avila-Vales, E. J. (2022) · Chaos Solitons & Fractals · doi:10.1016/j.chaos.2022.111844 · Cited by 19
Verkhivker, G. M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23062928 · Cited by 17
The nervous system during COVID ‐19: Caught in the crossfire
Natale, N. R., Lukens, J. R., & Petri, W. A. (2022) · Immunological Reviews · doi:10.1111/imr.13114 · Cited by 22
Aktaş, G., Balci, B., Yilmaz, Ş., Bardak, H., & Duman, T. T. (2022) · Journal of Bionic Memory · doi:10.53545/jbm.2022.22 · Cited by 18
“Some studies suggest this mutation can cause decreasing the vaccine-induced serum neutralizing antibody titer and can escape many authorized monoclonal antibodies [66-68].”
BackgroundChi, X., Xia, L., Zhang, G., Chi, X., Huang, B., Zhang, Y., Chen, Z., Han, J., Wu, L., Li, Z., et al. (2023) · Cell Discovery · doi:10.1038/s41421-023-00535-1 · Cited by 17
Protein nanoparticle vaccines induce potent neutralizing antibody responses against MERS-CoV
Chao, C. W., Sprouse, K. R., Miranda, M. C., Catanzaro, N., Hubbard, M. L., Addetia, A., Stewart, C., Brown, J. T., Dosey, A. M., Valdez, A., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.115036 · Cited by 18
Self-citationCirculation and Evolution of SARS-CoV-2 in India: Let the Data Speak
Limaye, S., Kasibhatla, S. M., Ramtirthkar, M. R., Kinikar, M., Kale, M. M., & Kulkarni‐Kale, U. (2021) · Viruses · doi:10.3390/v13112238 · Cited by 19
“Additionally, the reduced neutralizing antibody response for other monoclonal antibodies and escape from cellular immune response in case of HLA-24 for L452R substitution has been reported [16,68,69].”
BackgroundFocosi, D., Franchini, M., Joyner, M. J., & Casadevall, A. (2022) · Vox Sanguinis · doi:10.1111/vox.13239 · Cited by 17
Verkhivker, G. M., Agajanian, S., Kassab, R., & Krishnan, K. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084376 · Cited by 19
Zhou, H., Ni, W., Huang, W., Wang, Z., Cai, M., & Sun, Y.-C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.834942 · Cited by 22
Emergence of SARS-CoV-2 Resistance with Monoclonal Antibody TherapyPreprint
Choudhary, M. C., Chew, K. W., Deo, R., Flynn, J. P., Regan, J., Crain, C. R., Moser, C., Hughes, M. D., Ritz, J., Ribeiro, R. M., et al. (2021) · medRxiv · doi:10.1101/2021.09.03.21263105 · Cited by 17
“We assessed the presence of previously confirmed bamlanivimab resistance mutations (L452R, E484K, E484Q, F490S, and S494P) 7,12 .”
BackgroundDey-Rao, R., Smith, G. R., Timilsina, U., Falls, Z., Samudrala, R., Stavrou, S., & Melendy, T. (2021) · Antiviral Research · doi:10.1016/j.antiviral.2021.105183 · Cited by 17
“10 arising strains that may be vaccine resistant (McCallum et al., 2021), as well as novel CoVs that may arise in the future.”
Zhao, L. P., Lybrand, T. P., Gilbert, P. B., Hawn, T. R., Schiffer, J. T., Stamatatos, L., Payne, T. H., Carpp, L. N., Geraghty, D. E., & Jerome, K. R. (2021) · Viruses · doi:10.3390/v14010009 · Cited by 16
“The L452R mutation was recently shown to reduce binding affinity to some RBD-targeting monoclonal antibodies, as well as to reduce susceptibility to nAbs [28].”
BackgroundReduced neutralization of SARS-CoV-2 B.1.617 variant by convalescent and vaccinated sera
Hu, J., Wei, X., Jin, X., Peng, P., Xu, F.-L., Wu, K., Luo, F., Jin, A., Fang, L., Liu, B., et al. (2021) · Genes & Diseases · doi:10.1016/j.gendis.2021.11.007 · Cited by 27
“429 variant Spike also contributes to its escape from NAbs.(36,37) The limitation of this study include its small sample size, only focus on pseudovirus-based antibody neutralization in cell culture, and the possibility that mutations may alter neutralization by modulating Spike function rather than its antigenicity.”
InfluentialDelshad, M., Sanaei, M., Pourbagheri‐Sigaroodi, A., & Bashash, D. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109128 · Cited by 21
Jin, X., Sun, X. J., Chai, Y., Bai, Y., Li, Y., Hao, T., Qi, J., Song, H., Wong, C. C. L., & Gao, G. F. (2022) · Science China Life Sciences · doi:10.1007/s11427-022-2168-8 · Cited by 19
“…email: catherine_wong@bjmu.edu.cn; George F. Gao, email: gaof@im.ac.cn) in VOCs, which are associated with altered transmissibility and extensive immune escape (McCallum et al., 2021; Zhang et al., 2021), while other mutations that occur outside the spike region in circulating variants are ignored.”
BackgroundQin, S., Huang, H., Xiao, W., Chen, K., He, X., Tang, X., Huang, Z., Zhang, Y., Duan, X., Fan, N., et al. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.01.010 · Cited by 16
“L452R (Epsilon, Iota, and Kappa) promotes viral replication and infectivity, and resistance to monoclonal antibodies 55 .”
BackgroundHamdy, M. E., El‐Deeb, A. H., Hagag, N. M., Shahein, M. A., Alaidi, O., & Hussein, H. A. (2023) · International Journal of Veterinary Science and Medicine · doi:10.1080/23144599.2023.2222981 · Cited by 21
“● This mutation has immune evasion effect and it could decline titer of antibody neutralization from 3 to 6 fold [64,95].”
BackgroundGayvert, K. M., McKay, S., Lim, W. K., Baum, A., Kyratsous, C. A., Copin, R., & Atwal, G. S. (2023) · npj Viruses · doi:10.1038/s44298-023-00007-z · Cited by 18
Kubik, S., Arrigo, N., Bonet, J., & Xu, Z. (2021) · Viruses · doi:10.3390/v13112114 · Cited by 17
“Structure-Based Prediction of the Impact of the Mutations on Spike Interactions We assessed the effect of W152 mutants on neutralizing antibody (nAb) recognition by generating single point mutants (W152C, W152L, and W152R) and evaluating their changes in binding free energy (ddG) against 5 different NTD-target antibod…”
BackgroundMethodResultInfluentialLin, X., Guo, L., Lin, S., Chen, Z., Yang, F., Yang, J., Wang, L., Wen, A., Duan, Y., Zhang, X., et al. (2022) · Emerging Microbes & Infections · doi:10.1080/22221751.2022.2095308 · Cited by 17
“specific monoclonal antibodies exert narrow binding efficiency and neutralization breadth [19,20], it is”
BackgroundMahmood, T. B., Hossan, M. I., Mahmud, S., Shimu, M. S. S., Alam, M. J., Bhuyan, M. M. R., & Emran, T. B. (2022) · Immunity Inflammation and Disease · doi:10.1002/iid3.683 · Cited by 17
“depicts that L452R mutation contributed to the reduction in neutralizing potential of 14 out of 35 RBD specific monoclonal antibodies (mAbs) and in another study conducted by McCallum et al.(57) showed that L452R mutations promotes viral replication hence infectivity of the virus by facilitating immune evasion from ce…”
ResultSARS-CoV-2 Variants: Mutations and Effective Changes
Park, G., & Hwang, B. H. (2021) · Biotechnology and Bioprocess Engineering · doi:10.1007/s12257-021-0327-3 · Cited by 17
“found that “The RBD L452R mutation reduced or abolished the neutralizing activity of 14 out of 35 RBD-specific monoclonal antibodies (mAbs), including three clinical-stage mAbs” [40].”
BackgroundThe atomic portrait of SARS‐CoV‐2 as captured by cryo‐electron microscopy
Fertig, T. E., Chiţoiu, L., Terinte‐Balcan, G., Peteu, V. E., Marta, D. S., & Gherghiceanu, M. (2021) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.17103 · Cited by 14
Convergence of immune escape strategies highlights plasticity of SARS-CoV-2 spike
Yu, X., Juraszek, J., Rutten, L., Bakkers, M. J. G., Blokland, S., Melchers, J. M., van den Broek, N. J. F., Verwilligen, A., Abeywickrema, P. D., Vingerhoets, J., et al. (2023) · PLoS Pathogens · doi:10.1371/journal.ppat.1011308 · Cited by 16
“S13I and P9L are the most frequent causes for the loss of Cys15 via the cleavage site shift mechanism, but direct mutation of Cys15 is also observed (Supplementary Table 3).”
BackgroundInfluentialRole of dietary supplements in the continuous battle against COVID‐19
Zaman, R., Ravichandran, V., & Tan, C. K. (2024) · Phytotherapy Research · doi:10.1002/ptr.8096 · Cited by 15
“However, it remains unclear to what extent the variants have modified tissue-specific or organ-specific disease progression (Kumar, Narayan, et al., 2021; McCallum et al., 2021).”
BackgroundSuppan, M., Stuby, L., Harbarth, S., Fehlmann, C. A., Achab, S., Abbas, M., & Suppan, L. (2021) · JMIR Serious Games · doi:10.2196/33003 · Cited by 18
“The almost incessant emergence of new variants is concerning [7]—all the more so as some variants have been shown to evade the immune response acquired by vaccination or by prior infection [8,9].”
BackgroundZepeda–Cervantes, J., Martínez-Flores, D., Ramírez‐Jarquín, J. O., Tecalco-Cruz, Á. C., Alavez-Pérez, N. S., Vaca, L. A., & Silva, R. E. S. (2022) · Viruses · doi:10.3390/v14010094 · Cited by 21
Roshdy, W. H., Kandeil, A., El‐Shesheny, R., Khalifa, M. K., Al-Karmalawy, A. A., Showky, S., Naguib, A. M., Elguindy, N., Fahim, M., Elsood, H. A., et al. (2022) · Pathogens · doi:10.3390/pathogens11080834 · Cited by 15
“429 pseudoviruses have been reported [12,17,18].”
New insights into human immune memory from SARS‐CoV ‐2 infection and vaccination
Hartley, G. E., Edwards, E. S. J., O’Hehir, R. E., & van Zelm, M. C. (2022) · Allergy · doi:10.1111/all.15502 · Cited by 17
Verkhivker, G. M., Agajanian, S., Kassab, R., & Krishnan, K. (2022) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.2c00124 · Cited by 18
Evolution of Sequence and Structure of SARS-CoV-2 Spike Protein: A Dynamic Perspective
Sinha, A., Sangeet, S., & Roy, S. (2023) · ACS Omega · doi:10.1021/acsomega.3c00944 · Cited by 15
Wang, F., Huang, B., Deng, Y., Zhang, S., Liu, X., Wang, L., Liu, Q., Zhao, L., Tang, L., Wang, W., et al. (2023) · BMC Medicine · doi:10.1186/s12916-023-02942-3 · Cited by 15
“Background The ongoing COVID-19 pandemic has caused emergence of SARS-CoV-2 variants [1].”
BackgroundWhat makes SARS‐CoV‐2 unique? Focusing on the spike protein
Qian, J., Zhang, S.-C., Wang, F., Li, J., & Zhang, J. (2024) · Cell Biology International · doi:10.1002/cbin.12130 · Cited by 17
Subsequent Waves of Convergent Evolution in SARS-CoV-2 Genes and Proteins
Focosi, D., Spezia, P. G., & Maggi, F. (2024) · Vaccines · doi:10.3390/vaccines12080887 · Cited by 17
Evolutionary dynamics of the severe acute respiratory syndrome coronavirus 2 genomes
Qian, Z., Li, P., Tang, X., & Lü, J. (2022) · Medical Review · doi:10.1515/mr-2021-0035 · Cited by 14
Mycobacterium manresensis induces trained immunity in vitro
de Homdedeu, M., Sánchez-Moral, L., Violán, C., Ràfols, N., Ouchi, D., Martín, B., Peinado, M. A., Rodríguez, A., Arch, M., Perez‐Zsolt, D., et al. (2023) · iScience · doi:10.1016/j.isci.2023.106873 · Cited by 13
Tuning DNA Dissociation from Spherical Nucleic Acids for Enhanced Immunostimulation
Dittmar, J. W., Teplensky, M. H., Evangelopoulos, M., Qin, L., Zhang, B., & Mirkin, C. A. (2023) · ACS Nano · doi:10.1021/acsnano.3c04333 · Cited by 14
Kao, H., Orry, A. J. W., Palfreyman, M. G., & Porton, B. (2022) · Scientific Reports · doi:10.1038/s41598-022-14194-x · Cited by 12
Verkhivker, G. M., Agajanian, S., Kassab, R., & Krishnan, K. (2022) · Physical Chemistry Chemical Physics · doi:10.1039/d2cp01893d · Cited by 12
Castelli, M., Baj, A., Criscuolo, E., Ferrarese, R., Diotti, R. A., Sampaolo, M., Novazzi, F., Gasperina, D. D., Focosi, D., Ferrari, D., et al. (2021) · Viruses · doi:10.3390/v13081514 · Cited by 15
Nunes, D. R., Braconi, C. T., Ludwig‐Begall, L. F., Arns, C. W., & Durães‐Carvalho, R. (2022) · PLoS ONE · doi:10.1371/journal.pone.0268389 · Cited by 16
SARS‐CoV‐2 evolves to reduce but not abolish neutralizing action
Zhang, Y., Ndzouboukou, J. B., Lin, X., Hou, H., Wang, F., Yuan, L., Gan, M., Yao, Z., Fu, H., Cao, J., et al. (2022) · Journal of Medical Virology · doi:10.1002/jmv.28207 · Cited by 12
“L452R was shown to be associated with the escaping neutralization of several monoclonal and polyclonal antibodies.(35) Simultaneously, T478K enhanced the binding ability with ACE2.”
BackgroundManrique, P. D., Chakraborty, S., Henderson, R. C., Edwards, R. J., Mansbach, R. A., Nguyen, K., Stalls, V., Saunders, C., Mansouri, K., Acharya, P., et al. (2022) · iScience · doi:10.1016/j.isci.2022.105855 · Cited by 16
“As a background, residue 452 was extensively characterized as part of the California variant, and it impacted infectivity and resistance to neutralizing antibodies.(42) Deletions in this variant account for nearly 0.”
Miersch, S., Sharma, N., Saberianfar, R., Chen, C., Caccuri, F., Zani, A., Caruso, A., Case, J. B., Diamond, M., Amarasinghe, G. K., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110905 · Cited by 14
Differential escape of neutralizing antibodies by SARS-CoV-2 Omicron and pre-emergent sarbecovirusesPreprint
Wang, L., Tan, C. W., Chia, W. N., Zhu, F., Young, B. E., Chantasrisawad, N., Hwa, S.-H., Yeoh, A. Y.-Y., Lim, B. L., Yap, W. C., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1362541/v1 · Cited by 14
Barsi, S., Papp, H., Valdeolivas, A., Tóth, D. J., Kuczmog, A., Madai, M., Hunyady, L., Várnai, P., Sáez-Rodríguez, J., Jakab, F., et al. (2022) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1010021 · Cited by 14
“Identification of new therapeutic compounds against SARS-CoV-2 / COVID-19 is an urgent need until effective vaccination is worldwide available and given the emergence of SARS-CoV-2 strains showing immune evasion [2].”
BackgroundZhang, Z., Wan, X., Li, X., & Wan, C. (2022) · Molecules · doi:10.3390/molecules27196688 · Cited by 12
“though mass spectrometry and structural studies, revealing that the S13I mutation resulted in total loss of neutralization for 10 of 10 NTD‐specific mAbs be‐ cause the NTD antigenic supersite was remodeled by a shift of the signal peptide cleav‐ age site and the formation of a new disulfide bond [40].”
BackgroundAn update on SARS-CoV-2 immunization and future directions
Rana, R., Kant, R., Kumra, T., Gupta, S. V., Rana, D. S., & Ganguly, N. K. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1125305 · Cited by 14
“RBD mutations in the epsilon, beta, and theta variants resulted in an increase in infectivity in vitro and also made the virus 20% more transmissible (Ali et al., 2021a; Deng et al., 2021; McCallum et al., 2021; Zhao et al., 2021).”
BackgroundThe Key Site Variation and Immune Challenges in SARS-CoV-2 Evolution
Liu, Y., & Ye, Q. (2023) · Vaccines · doi:10.3390/vaccines11091472 · Cited by 12
“This mutation reduced neutralizing activity in 14 of 34 RBD-specific mAbs, and 10 of them experienced a decline of 10-fold or more in their neutralization potency [74].”
BackgroundAn Antigenic Space Framework for Understanding Antibody Escape of SARS-CoV-2 Variants
Miller, N. L., Clark, T., Raman, R., & Sasisekharan, R. (2021) · Viruses · doi:10.3390/v13102009 · Cited by 10
“Such a pan-epitope effect is supported experimentally for certain residues within the Pan-Supersite cluster such as W152, for which the W152C mutation was shown to escape binding from every NTD-directed tested [55].”
BackgroundModeling the Transmission of the SARS-CoV-2 Delta Variant in a Partially Vaccinated Population
de León, U. A.-P., Avila-Vales, E. J., & Huang, K. (2022) · Viruses · doi:10.3390/v14010158 · Cited by 13
“While most of the approved vaccines still demonstrate effectiveness against SARS-CoV-2, the delta variant’s enhanced transmission rate and resistance to vaccines [17] imply that the trajectory of the COVID-19 pandemic will depend on several parameters associated with vaccine-induced immunity against new variants.”
BackgroundInfluentialKodchakorn, K., & Kongtawelert, P. (2022) · PLoS ONE · doi:10.1371/journal.pone.0277745 · Cited by 12
Verstraete, M. M., Heinkel, F., Li, J., Cao, S., Tran, A., Halverson, E. C., Gene, R. W., Stangle, E., Silva‐Moreno, B., Arrafi, S., et al. (2023) · mAbs · doi:10.1080/19420862.2023.2212415 · Cited by 12
Increased vaccine sensitivity of an emerging SARS-CoV-2 variant
Lewnard, J. A., Hong, V. X., Kim, J. S., Shaw, S. F., Lewin, B. J., Takhar, H. S., Lipsitch, M., & Tartof, S. Y. (2023) · Nature Communications · doi:10.1038/s41467-023-39567-2 · Cited by 11
Lim, C. P., Kok, B. H., Lim, H. T., Chuah, C., Abdul‐Rahman, B., Majeed, A. B. A., Wykes, M., Leow, C. Y., & Leow, C. Y. (2022) · Pathogens and Global Health · doi:10.1080/20477724.2022.2072456 · Cited by 12
“convalescent and mRNA vaccine-elicited sera [59].”
Wang, B., Xu, J., Wu, S., Zhang, Z., Zhao, Z., Zhang, J., Fu, L. L., Zai, X., Wang, Y., Zhang, G., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01065-0 · Cited by 12
SARS-CoV-2 Delta Variant: Interplay between Individual Mutations and Their Allosteric Synergy
Chan, C., Song, Y., Xu, Z., Shang, C., & Zhou, R. (2022) · Biomolecules · doi:10.3390/biom12121742 · Cited by 12
An encodable multiplex microsphere-phase amplification sensing platform detects SARS-CoV-2 mutations
Zhong, Z., Wang, J., He, S., Su, X., Huang, W., Chen, M., Zhuo, Z., Zhu, X., Fang, M., Li, T., et al. (2022) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2022.114032 · Cited by 12
A SARS-CoV-2: Companion Animal Transmission and Variants Classification
Pandit, R., & Matthews, Q. L. (2023) · Pathogens · doi:10.3390/pathogens12060775 · Cited by 15
Ghoula, M., Kongmeneck, A. D., Eid, R., Camproux, A., & Moroy, G. (2023) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.3c01467 · Cited by 12
GB-2 blocking the interaction between ACE2 and wild type and mutation of spike protein of SARS-CoV-2
Tsai, M., Yang, Y., Lin, Y., Chang, G., Hsu, C., Yeh, R., Shu, L., Cheng, Y., Liu, H.-T., Wu, Y.-H., et al. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112011 · Cited by 10
Calderón‐Torres, M., Ortiz-Reyes, A. E., & Murguía‐Romero, M. (2022) · Current Molecular Medicine · doi:10.2174/1566524022666220324114027 · Cited by 10
Verkhivker, G. M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23042172 · Cited by 10
Mehra, R., & Kepp, K. P. (2022) · European Biophysics Journal · doi:10.1007/s00249-022-01619-8 · Cited by 10
Relative Consolidation of the Kappa Variant Pre-Dates the Massive Second Wave of COVID-19 in India
Singh, J., Malhotra, A. G., Biswas, D., Shankar, P., Lokhande, L., Yadav, A. K., Raghuvanshi, A., Kale, D., Nema, S., Saigal, S., et al. (2021) · Genes · doi:10.3390/genes12111803 · Cited by 10
C57BL/6J Mice Are Not Suitable for Modeling Severe SARS-CoV-2 Beta and Gamma Variant Infection
Currey, J. M., Rabito, F., Maness, N. J., Blair, R. V., Rappaport, J., Qin, X., Kolls, J. K., & Srivastava, A. K. (2022) · Viruses · doi:10.3390/v14050966 · Cited by 10
“However, this was at an earlier time point, 2 days post-exposure [1,3,4].”
BackgroundInfluentialTerada, M., Kondo, N., Wanifuchi‐Endo, Y., Fujita, T., Asano, T., Hisada, T., Uemoto, Y., Kato, A., Yamanaka, N., Sugiura, H., et al. (2022) · Breast Cancer Research and Treatment · doi:10.1007/s10549-022-06693-2 · Cited by 12
RASCL: Rapid Assessment of Selection in CLades through molecular sequence analysis
Lucaci, A. G., Zehr, J. D., Shank, S. D., Bouvier, D., Ostrovsky, A., Han, M., Nekrutenko, A., Martin, D. P., & Pond, S. L. K. (2022) · PLoS ONE · doi:10.1371/journal.pone.0275623 · Cited by 14
“To gather this information, computational and laboratorybased analytical approaches have been used to test and validate hypotheses about the observed genotype and phenotypic implications [54].”
MethodTragni, V., Mercurio, I., Paoletti, D. P., Onofrio, A., Laera, L., Beltrame, L. C., Sgobba, M. N., Guerra, L., Volpicella, M., Grassi, A., et al. (2023) · Journal of Medical Virology · doi:10.1002/jmv.28875 · Cited by 10
“18 In this context, a few neutralizing monoclonal ab and nb have already been employed in clinics, and their crystallized structures, in complex with the SARS ‐ CoV ‐ 2 spike RBD, have been solved and made available through the protein data bank (PDB).”
BackgroundMethodInfluentialStructural Basis for the Enhanced Infectivity and Immune Evasion of Omicron Subvariants
Li, Y., Shen, Y., Zhang, Y., & Yan, R. (2023) · Viruses · doi:10.3390/v15061398 · Cited by 11
Verkhivker, G. M., Agajanian, S., Kassab, R., & Krishnan, K. (2022) · Biomolecules · doi:10.3390/biom12070964 · Cited by 11
“429 (epsilon) variants showing that the intrinsic conformational flexibil- 94 ity of the S protein variants can be controlled by mutations and determine their ability 95 to evade host immunity and incur resistance to antibodies [32-35].”
BackgroundDor, G., Kekana, D., Hisner, R., Martin, D. P., Korber, B., Ernst, T., Levy, A., Speers, D. J., Turville, S. G., Sintchenko, V., et al. (2026) · Virus Evolution · doi:10.1093/ve/veag016 · Cited by 16
Deschambault, Y., Lynch, J., Warner, B. M., Tierney, K. J., Huynh, D., Vendramelli, R., Tailor, N., Frost, K. L., Sajesh, B. V., LeBlanc, K., et al. (2022) · Journal of Virology · doi:10.1128/jvi.00389-22 · Cited by 9
Caputo, E., & Mandrich, L. (2022) · Life · doi:10.3390/life12081245 · Cited by 12
“In fact, the L5F mutation is localized in the signal peptide (SP) of the spike; it has been observed that mutations of SP alter the spike functionality [35].”
BackgroundPetitjean, S. J. L., Eeckhout, S., Delguste, M., Zhang, Q., Durlet, K., & Alsteens, D. (2023) · Nano Letters · doi:10.1021/acs.nanolett.3c03550 · Cited by 9
Liu, H., Wang, S., Yang, S., Luo, S. X., Jie, J., Hua, S., Peng, L., Luo, J., Song, L., & Li, D. (2022) · Journal of Translational Internal Medicine · doi:10.2478/jtim-2022-0054 · Cited by 13
Reduced neutralization of SARS-CoV-2 B.1.617 variant by inactivated and RBD-subunit vaccinePreprint
Hu, J., Wei, X., Jin, X., Peng, P., Xu, F.-L., Wu, K., Luo, F., Jin, A., Fang, L., Liu, B., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.07.09.451732 · Cited by 9
van Oosterhout, C., Stephenson, J. F., Weimer, B. C., Ly, H., Hall, N., & Tyler, K. M. (2021) · Virulence · doi:10.1080/21505594.2021.1960109 · Cited by 9
“risk of vaccine-resistant strains emerging through antigenic drift [2].”
BackgroundOliveira, M. D. M., Schemberger, M. O., Suzukawa, A. A., Riediger, I. N., Debur, M. D. C., Becker, G., Resende, P. C., Gräf, T., Balsanelli, E., Baura, V. A., et al. (2021) · Virology Journal · doi:10.1186/s12985-021-01690-1 · Cited by 18
Reduced levels of convalescent neutralizing antibodies against SARS-CoV-2 B.1+L249S+E484K lineage
Álvarez-Díaz, D. A., Laiton‐Donato, K., Torres, O., Ruiz-Moreno, H. A., Franco-Muñoz, C., Beltran, M. A., Mercado, M., Rueda, M. G., & Muñoz, A. L. (2021) · Virus Research · doi:10.1016/j.virusres.2021.198629 · Cited by 8
Clinical features of children with coronavirus disease 2019 caused by Delta variant infection.
Sheng, J.-F., Shao, L., & Wang, Y. (2021) · PubMed Central · doi:10.7499/j.issn.1008-8830.2110043 · Cited by 8
Hydroxypropyl-Beta Cyclodextrin Barrier Prevents Respiratory Viral Infections: A Preclinical Study
Lu, A., Ebright, B., Naik, A., Tan, H. L., Cohen, N. A., Bouteiller, J., Lazzi, G., Louie, S., Humayun, M., & Asante, I. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25042061 · Cited by 9
Li, Y., Fan, Q., Zhou, B., Shen, Y., Zhang, Y., Cheng, L., Qi, F., Song, S., Guo, Y., Yan, R., et al. (2022) · iScience · doi:10.1016/j.isci.2022.104431 · Cited by 9
Stäb, S., Pearce, N. M., Tronrud, D. E., Ginn, H. M., Fadda, E., Santoni, G., & Thorn, A. (2024) · Crystallography Reviews · doi:10.1080/0889311x.2024.2363756 · Cited by 7
Yaghoobizadeh, F., Ardakani, M. R., Ranjbar, M. M., Galehdari, H., & Khosravi, M. (2022) · Protein Expression and Purification · doi:10.1016/j.pep.2022.106210 · Cited by 10
Immordino, P., Pisciotta, V., Amodio, E., Bonura, C., Bonura, F., Cacioppo, F., Calamusa, G., Capra, G., Casuccio, A., Grazia, S. D., et al. (2023) · Vaccines · doi:10.3390/vaccines11111702 · Cited by 8
Gasparini, P., Philot, E. A., Pantaleão, S. Q., Bonfim, N. E. S. M. T., Kliousoff, A., Quiroz, R. N., Pérahia, D., Simões, R. P., Magro, A. J., & Scott, A. L. (2023) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2023.108443 · Cited by 10
Tracking the Genomic Evolution of SARS-CoV-2 for 29 Months in South Korea
Jeong, S., Kim, J., Lee, S. K., Cho, E., Hyun, J., Song, W., & Kim, H. S. (2023) · Viruses · doi:10.3390/v15040873 · Cited by 7
“Compared with the wild-type strain, the Epsilon variant showed a three-fold decrease in neutralizing titers after vaccinations due to remodeling of the peptide cleavage site and formation of a disulfide bond derived from S13I and W152C mutations [43].”
BackgroundSpatiotemporal transmission of SARS-CoV-2 lineages during 2020–2021 in Pernambuco—Brazil
Machado, L. C., Dezordi, F. Z., de Lima, G. B., de Lima, R. E., Silva, L. C. A., Pereira, L. D. M., da Silva, A. F., Neto, A. M. D. S., de Oliveira, A. L. S., Armstrong, A. D. C., et al. (2024) · Microbiology Spectrum · doi:10.1128/spectrum.04218-23 · Cited by 6
Biswas, S., Mahmud, S., Mita, M. A., Afrose, S., Hasan, M. R., Paul, G. K., Shimu, M. S. S., Uddin, M. S., Zaman, S., Park, M. N., et al. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.825245 · Cited by 6
Lina, B. (2021) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/j.banm.2021.11.002 · Cited by 9
Rostamzadeh, S., Allafasghari, A., Allafasghari, A., & Abouhossein, A. (2024) · Scientific Reports · doi:10.1038/s41598-024-71034-w · Cited by 9
Viral syncytia evolve to resist interferon
Li, T., Kang, I., Ye, J., Hu, Z., Gibbs, J. S., Ye, C., Takeda, K., Košík, I., Shi, G., Hollý, J., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-74676-8 · Cited by 6
Fragoso-Saavedra, M., Ramírez-Estudillo, C., Peláez-González, D. L., Ramos-Flores, J. O., Torres-Franco, G., Núñez-Muñoz, L. A., Marcelino-Pérez, G., Segura-Covarrubias, M. G., González‐González, R., Ruíz‐Medrano, R., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.848054 · Cited by 7
“Each VOC has different mutations across its genome, including the gene coding for the spike (S) protein employed in the current commerciallyavailable vaccines, affecting the potency of vaccine-elicited nAbs (39, 40).”
BackgroundHamdy, M. E., El‐Deeb, A. H., Hagag, N. M., Shahein, M. A., Alaidi, O., & Hussein, H. A. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.875123 · Cited by 7
Metadata
- Authors
- McCallum, M., Bassi, J., De Marco, A., Chen, A., Walls, A. C., Di Iulio, J., Tortorici, M. A., Navarro, M.-J., Silacci-Fregni, C., Saliba, C., Sprouse, K. R., Agostini, M., Pinto, D., Culap, K., Bianchi, S., Jaconi, S., Cameroni, E., Bowen, J. E., Tilles, S. W., Pizzuto, M. S., Guastalla, S. B., Bona, G., Pellanda, A. F., Garzoni, C., Van Voorhis, W. C., Rosen, L. E., Snell, G., Telenti, A., Virgin, H. W., Piccoli, L., Corti, D., & Veesler, D.
- Affiliations
- University of Washington (US)
- Vir Biotechnology (Switzerland) (CH)
- Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.
- VIR Biotechnology (United States) (US)
- Vir Biotechnology, San Francisco, CA 94158, USA.
- Independent physician, 6828 Balerna, Switzerland.
- Clinica Luganese Moncucco (CH)
- Clinical Research Unit, Clinica Luganese Moncucco, 6900 Lugano, Switzerland.
- Center for Emerging and Re-emerging Infectious Diseases, Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington School of Medicine, Seattle, WA 98195, USA.
- Corresponding author
- McCallum, Matthew
- Bassi, Jessica
- Chen, Alex
- Walls, Alexandra C.
- Piccoli, Luca
- Corti, Davide
- Veesler, David
- ORCID
- McCallum, Matthew
- Bassi, Jessica
- De Marco, Anna
- Chen, Alex
- Walls, Alexandra C.
- Di Iulio, Julia
- Tortorici, M. Alejandra
- Navarro, Mary-Jane
- Saliba, Christian
- Sprouse, Kaitlin R.
- Pinto, Dora
- Culap, Katja
- Bianchi, Siro
- Jaconi, Stefano
- Cameroni, Elisabetta
- Bowen, John E.
- Tilles, Sasha W.
- Pizzuto, Matteo Samuele
- Guastalla, Sonja Bernasconi
- Bona, Giovanni
- Pellanda, Alessandra Franzetti
- Garzoni, Christian
- Van Voorhis, Wesley C.
- Rosen, Laura E.
- Snell, Gyorgy
- Telenti, Amalio
- Virgin, Herbert W.
- Piccoli, Luca
- Corti, Davide
- Veesler, David
- Venue
- Science
- Published
- 2021-08-06
- Volume
- 373
- Issue
- 6555
- Pages
- 648-654
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC9835956
- OpenAlex
- W3174747632
- Cited by
- 412
- References
- 90
- Citations by year
- 2026: 12 · 2025: 13 · 2024: 25 · 2023: 56 · 2022: 165 · 2021: 141
- FWCI
- 31.48
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Science (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- National Institute of Allergy and Infectious Diseases (DP1AI158186, HHSN272201700059C, U01 AI151698-01)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
- Life Sciences › Agricultural and Biological Sciences › Animal Science and Zoology › Animal Virus Infections Studies
- Keywords
- SARS-CoV-2, immune evasion, spike protein mutations, L452R, N-terminal domain, receptor binding domain, neutralizing antibodies, monoclonal antibodies, signal peptide cleavage site, disulfide bonds, mRNA vaccines, convalescent plasma, neutralization titers
- MeSH terms
- Protein Domains, COVID-19, SARS-CoV-2, COVID-19 Vaccines, BNT162 Vaccine, 2019-nCoV Vaccine mRNA-1273, Antibodies, Monoclonal, Antibodies, Viral, Antigens, Viral, Humans, Models, Molecular, Mutation, Neutralization Tests, Protein Conformation, Amino Acid Substitution, Cryoelectron Microscopy, Protein Subunits, Protein Interaction Domains and Motifs, Immune Evasion, Antibodies, Neutralizing, Spike Glycoprotein, Coronavirus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.